Pregnant women and infants are at risk should they contract mpox but there are no approved vaccines for this population.

While Bavarian Nordic’s vaccine Jynneos is approved in several countries to prevent mpox and smallpox infections in adults, there has been a lack of data to support its approval in adolescents.

(Reuters) - An initial 899,000 vaccine doses have been allocated for 9 countries across Africa that have been hit hard by the ...

(Reuters) -The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to ...

An independent study has found that Bavarian Nordic's mpox vaccine Jynneos – currently only authorised for use in adults in the US – is also safe and generates a strong antibody response in ...

An initial 899,000 vaccine doses have been allocated for nine countries across Africa that have been hit hard by the current mpox surge, the WHO and other health organizations say.

A clinical trial by the US National Institutes of Health (NIH) has shown that Bavarian Nordic’s mpox vaccine induced an antibody response in adolescents equivalent to that of adults. The interim ...

The World Health Organisation has okayed Bavarian Nordic's mpox vaccine for young persons, aged between 12 and 17, as they are particularly believed to be vulnerable to outbreaks of the viral ...

The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the ...